Happel David

Happel David is listed in filings as President & CEO at Sagimet Biosciences Inc.. This profile follows SEC Form 4 activity through Jun 1, 2026, including sale activity. Recent filings connect the profile to Sagimet Biosciences Inc. (SGMT). The current snapshot covers public activity from Feb 7, 2025 to Jun 1, 2026. Reported amounts are shown as $2.2M to $64.9K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.